

NewSpring Healthcare



STRATEGY OVERVIEW

NewSpring Healthcare is NewSpring's thesis-driven growth equity strategy focused on partnering with healthcare companies addressing key issues that positively impact health outcomes across the care continuum.


NewSpring Healthcare is part of NewSpring, a lower-middle-market focused private equity firm that partners with innovators, makers, and operators of highperforming companies in dynamic industries to catalyze new growth and seize compelling opportunities. The Firm manages approximately \$3.5 billion across five distinct strategies covering the spectrum from growth equity and control buyouts to mezzanine debt.

NEWSPRING HEALTHCARE INVESTMENT CRITERIA

Financials \$10mm-\$100m TTM Revenue	I M - Rec - Hig - Sus	h-growth profile – Cap		Tech-Enabled Healthcare Services	Sample Indu	al Specialty)) als
Differentiating Factors				Growth by the Numbers			
 20+ years of investing in self- sustainable companies and providing the necessary financi and operational resources to ensure growing companies mat to the next level 	approa al challer naviga	tionally-oriented part ach to help CEOs pre nges and assist in ting complex financia unities before they o	dict	\$633m NewSpring Healthcar	e AUM	\$5-\$20mm	
 180+ years of combined operati experience in health sciences a a commitment to leveraging it in a way that helps transformative companies continue to grow 	nd provid n resour metho enable	enced Advisory Boar es upper-market ces, proven operatio dologies, and techno ment to critical funct within the portfolio	nal logy	In fast-growing healthcare busines	1	-5% Growth R Post-investment with NewSpring's value add	ate
INVESTMENT TEAM NewSpring Healthcare's investment	team possesses	s deep domain exper	ience and a pa	assion for healthcare	Matt Giangjordano	Charlie Aprahamian	
ADVISORY PARTNERS	Каріан	myers	Ruwe	Debacco	Changlordano	Apronomian	
NewSpring Healthcare's advisory pa	artners leverage	real operational exp	ertise to create	e value			

ABOUT NEWSPRING

Investments Made since 1999



~\$3.5bn

Pete Buzy Former CEO; Paragon Bioservices

Bruce Downey Former CEO; Barr Pharmaceuticals

> 100+ Total Exits

Mark Pacala Director; Verisma

70+ NewSpring Employees

5

Assets Under Management

Investment Strategies







CONTACT

For investment opportunities or questions, please contact: Adam VeVerka at 610.567.2392 or aveverka@newspringcapital.com Andrew DeBacco at 610.947.6163 or adebacco@newspringcapital.com

OUR LOCATIONS

Philadelphia • Baltimore • Chicago • Denver • New York Phone: 610.567.2380 • Fax: 610.567.2388 • newspringcapital.com

SPECIALTY